Introduction
Despite the steady decline in death rates from cardiovascular disease during the last decades, cardiovascular disease continues to be one of the biggest health care problems in terms of burden of disease and health care costs (http://www.who.int/en/). The beneficial effects of statins in the primary and secondary prevention of cardiovascular disease are well established (Baigent et al., 2005; Heart Protection Study Collaborative Group, 2002) . These benefits are primarily attributed to the lipid-lowering properties of statins: it has been estimated that statins reduce low-density-lipoprotein (LDL)-cholesterol levels by 18-55% (Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, 2002; Jones et al., 2003; Law et al., 2003) . In addition to this cholesterol-lowering activity, statins possess multiple pleiotropic effects (Ray and Cannon, 2005; Ray and Cannon, 2007) . In Europe, current recommendations for cardiovascular risk management are based on the Systematic COronary Risk Evaluation (SCORE)-risk charts (Conroy et al., 2003; De Backer et al., 2003) . In 2006, for The Netherlands an adapted SCORE-risk chart has been developed using national data (Dutch Institute for Healthcare Improvement and Dutch College of General Practitioners, 2006) . From the charts, the 10-year absolute risk of fatal cardiovascular disease can be derived, taking into account several risk factors (gender, age, smoking, systolic blood pressure, and serum total cholesterol or total/HDL-cholesterol ratio). According to the Dutch guidelines, treatment with a statin in the primary prevention of cardiovascular disease is recommended for all persons with a 10-year SCORE-risk of fatal cardiovascular disease ≥ 10%, unless LDL-cholesterol is less than 2.5 mmol/l. For subjects with type 2 diabetes mellitus or established cardiovascular disease, treatment is recommended for all persons with LDL-cholesterol ≥ 2.5 mmol/l. The use of functional foods enriched with phytosterols and phytostanols is an alternative strategy to lower elevated total and LDL-cholesterol levels. Phytostanol-and phytosterol-enriched mar-garines were launched on the Dutch market in 1999 and 2000, respectively and its use has increased in the past years in both users and non-users of statins (Eussen et al., unpublished data) . In a recent meta-analysis, Demonty et al. (2009) found that a daily dose of 2.15 g phytosterols/-stanols reduces LDL-cholesterol by 8.8%. Furthermore, phytosterols and -stanols seem to be equally effective in both statin users and statin non-users (Eussen et al., 2010a) . It is generally assumed that phytosterols/-stanols will decrease coronary heart disease by lowering cholesterol levels, although there are no studies yet to confirm this (Katan et al., 2003) . The guidelines for cardiovascular risk management recommend that all persons with a 10-year SCORE-risk ≥5% should be given lifestyle recommendations, including the encouragement of the use of phytosterols/-stanols as part of a healthy diet (Dutch Institute for Healthcare Improvement and Dutch College of General Practitioners, 2006; Law, 2000) .
There is currently no universal screening for risk factors of cardiovascular disease in The Netherlands, nor in any other EU country. Consequently, the detection of high cholesterol values and other cardiovascular disease risk factors occurs primarily through clinical case-finding. As a result many people are unaware that they are at high risk for cardiovascular disease and could benefit from statin and/or phytosterol/-stanol use (Mantel-Teeuwisse et al., 2003) .
The aging of the population together with the rising health care costs requires considering the cost-effectiveness and budgetary impact of different intervention strategies. In cost-effectiveness analyses the costs and health effects of an intervention are compared to determine whether the intervention provides value-for-money (Morris et al., 2007) . Statins have been assessed for cost-effectiveness in a range of publications (for review see Franco et al. (2005) and Gumbs et al. (2007) ), and were found to be cost-effective for high risk patients (Franco et al., 2005; Ward et al., 2007) . In contrast, to date only two studies evaluated the cost-effectiveness of phytosterols or -stanols (Gerber et al., 2006; Martikainen et al., 2007) . In both studies it was concluded that phytosterols and -stanols are (potentially) cost-effective under optimal conditions of use, i.e. taking the daily recommended amount of 2 g phytosterols/-stanols (without discontinuation). However, neither study included an economic evaluation in which real-life consumption patterns of phytosterols/-stanols were taken into account, nor were all health benefits and costs considered. Moreover, the incremental costs and health effects of phytosterols/-stanols in addition to statins have not been evaluated. Therefore, the present study aimed to evaluate the health benefits, i.e. the prevention of cardiovascular disease, and health care costs of functional foods enriched with phytosterols/-stanols in addition to statin therapy, taking into account the intake levels and discontinuation rates as observed in daily practice.
Methods
The cost-effectiveness of the use of functional foods with phytosterols/-stanols as monotherapy and as add-on to statin therapy was estimated both in a real-life situation, i.e. passive clinical casefinding to identify subjects eligible for treatment with statins, and in a theoretical maximum situation, i.e. assuming that free populationbased screening is implemented resulting in known 10-year SCORErisks for the whole Dutch population between 35 and 75 years of age and all subjects with a SCORE-risk ≥10% are treated with statins. This theoretical situation gives information about the maximum health benefits that can be achieved with phytosterols/-stanols in addition to optimal statin therapy.
In both the real-life and theoretical maximum situation, long-term disease prevalence and mortality rates, as well as health care resource use, were simulated and compared for two scenarios using the RIVM Chronic Disease Model (Section 2.2). The first scenario is the current situation in which functional foods enriched with phytosterols/-stanols are used as customary in the Dutch population. A large part of the population does not use phytosterols/-stanols, whereas others use them on their own initiative or on general practitioner's advice. In the second scenario an increase in phytosterol/-stanol use is considered, both as a monotherapy for subjects with a modestly elevated risk (SCORE-risk ≥5%, b10%), and as add-on to statin therapy for subjects with a highly elevated risk (SCORE-risk ≥10%) (Table 1) .
Scenarios

Real-life (RL) situation
In a clinical case-finding or real-life situation the SCORE-risk is only known for subjects who have their cholesterol level and blood pressure assessed, presumably the ones that are susceptible to a high risk of cardiovascular events and/or health-conscious people.
2.1.1.1. RL reference: real-life situation with customary phytosterol/-stanol use. The RL reference scenario assumed no additional phytosterol/-stanol use in a real-life situation. It reflects the real-life consumption patterns of phytosterols/-stanols, including actual daily intake levels and discontinuation rates (Sections 2.3.2 and 2.3.3). In this scenario population numbers, morbidity rates and health care costs of the Dutch population that was between 35 and 75 years of age in 2007 were simulated over a time horizon of 50 years. Data from the population-based Doetinchem Cohort Study were used to estimate subjects' 10-year SCORE-risk and current phytosterol/-stanol use in the Dutch population (Verschuren et al., 2008) . In this ongoing cohort study, participants are examined in consecutive 5-year intervals. The most recent data were used for the current study, collected during the years [2003] [2004] [2005] [2006] [2007] , which included about 4500 persons. Current statin and combined users of both statins and phytosterols/-stanols were identified by linking the data of each participant of the Doetinchem Cohort Study to their pharmacydispensing records using the Pharmacomorbidity-Record Linkage System (http://www.pharmo.nl/) (Eussen et al., 2010b).
2.1.1.2. RL plus PS: real-life situation with additional phytosterol/-stanol use. In the RL plus PS scenario subjects who have a known SCORE-risk ≥5% were assumed to start phytosterol/-stanol use. We assumed that in the Dutch population all current statin users had their SCORE-risk assessed at the beginning of their therapy and their SCORE-risk was ≥10%, conforming to the guidelines. These subjects start using phytosterols/-stanols. In addition, we assumed that subjects with a known modestly elevated risk (SCORE-risk ≥5, b10%) start using phytosterols/-stanols. However, in a real-life setting it is difficult to identify which fraction of the Dutch population has their SCORE-risks assessed and no general practitioners' data were available on which to make a reliable estimate. Therefore, we defined a minimum and maximum scenario for phytosterol/-stanol use. In the minimum reallife plus phytosterols/-stanols scenario (RL plus PS (min)), only current statin users start using phytosterols/-stanols, which results in a minimum number of additional phytosterol/-stanol users. In the maximum real-life plus phytosterols/-stanols scenario (RL plus PS (max)), both current statin users and all subjects with a SCORE-risk ≥5, b10% start using phytosterols/-stanols, resulting in a maximum number of additional phytosterol/-stanol users ( Table 1 ). The true number of additional phytosterol/-stanol users in the general population lies somewhere between these two extremes.
The cost-effectiveness of additional phytosterol/-stanol use in a real-life situation was obtained by subtracting the results of the real-life scenario (RL reference) from the scenarios with added phytosterols/-stanols (RL plus PS (min) and RL plus PS (max)).
Theoretical maximum (TM) situation
In the theoretical maximum situation it is assumed that the SCORE-risk for the whole Dutch population aged between 35 and 75 years is known. In this situation, all subjects with a 10-year SCORErisk ≥10% start using statins in both scenarios. Subjects already using statins before the start of the scenario were assumed to continue taking their current medication.
2.1.2.1. TM reference: maximum situation with customary phytosterol/ -stanol use. The TM reference scenario assumed customary use of phytosterols/-stanols in a situation with maximum statin use. It reflects the real-life consumption patterns of phytosterols/-stanols, including actual daily intake levels and discontinuation rates (Sections 2.3.2 and 2.3.3).
2.1.2.2. TM plus PS: maximum situation with additional phytosterol/-stanol use. In this scenario, we assumed phytosterol/-stanol use in all subjects with a 10-year SCORE-risk ≥ 5% and combined use of phytosterols/ -stanols and statins in all subjects with a 10-year SCORE-risk ≥10%. Because all current statin users supposedly have or had a SCORE-risk ≥10%, they were also assumed to start using phytosterols/-stanols (Table 1) .
The cost-effectiveness of additional phytosterol/-stanol use in the maximum situation was obtained by subtracting the results of the scenario without added phytosterols/-stanols (TM reference) from the scenario with added phytosterols/-stanols (TM plus PS).
The Chronic Disease Model
The RIVM Chronic Disease Model is a Markov-type, dynamic population-based model developed at the National Institute for Public Health and the Environment (RIVM) with the purpose to evaluate effects of public health policy on the incidence and prevalence of chronic diseases in the Dutch population Hoogenveen et al., 2010; van Baal et al., 2005) . The model links lifestyle and lifestyle related risk factors to morbidity and mortality using relative risks for disease incidence. It contains data on smoking, alcohol, cholesterol levels, blood pressure and food intake, as well as data on 13 chronic diseases (van Baal et al., 2005) . For the current application, the modelling of cholesterol in relation to cardiovascular disease is especially important. The Chronic Disease Model includes different relative risk estimates for acute myocardial infarction, stroke, and chronic heart failure, and accounts for interactions between these diseases, with for instance myocardial infarction increasing the risk of chronic heart failure ( Fig. 1) . For an example of a recent application of the model in the evaluation of nutritional effects on the risk of cardiovascular disease see Engelfriet et al. (2010) .
The Chronic Disease Model simulates effects on health and costs over the model's time horizon for a model population, accounting for a background rate of new phytosterol/-stanol and statin users and background changes in cholesterol level (e.g., due to aging) over time. The model population was stratified into four classes based on total cholesterol level, with cut-off values of 5.0, 6.5 and 8.0 mmol/l. Each class was further subdivided into two groups based on the use of statins (yes/no), resulting in eight different classes of cardiovascular risk. The incidence of cardiovascular disease is increased for higher classes of total cholesterol and absence of statin use (due to the pleiotropic effects of statins), and also, e.g., with higher age and male gender. Transitions between the classes are possible, reflecting starting or stopping the use of statins, and changes in total cholesterol level, e.g. due to increased phytosterol/-stanol use in our scenarios ( Fig. 1 ).
Model input data
General demographic data and data on risk factors and diseases
General demographic data on total mortality, birth rates and population size were obtained from Statistics Netherlands (http://statline.cbs.nl/statweb/). Age-and sex-specific initial prevalences of risk factors, including cholesterol levels, and transitions between risk factor classes were obtained from large representative Dutch Health monitoring studies (Hofman et al., 1995; Houterman et al., 2001; Verschuren et al., 2008; Westert et al., 2005) . Finally, data on disease specific prevalence, incidence, remission and mortality were obtained from four general practitioners' registrations (Donker, 2010; Engelfriet et al., 2011; Verheij et al., 2009; Verheij et al., 2010; Westert et al., 2005) .
Intake and effect of phytosterols/-stanols and statins
The average per person daily intake of phytosterols/-stanols in the scenarios with additional phytosterol/-stanol use was derived from the averages assessed in the Doetinchem Cohort Study by a food frequency questionnaire. The questionnaire contained an open question on the brand name of bread spread used (e.g. phytosterol/-stanol-enriched bread spreads) and photographs of 4 differently sized portions. The average intake level was 1.05 g phytosterols/-stanols per day. This intake level would cause a reduction in total cholesterol of 4.7% (95% CI: −7.2 to −3.2) based on the dose-response relation in the metaanalysis by Demonty et al. (2009) 
The use of different types and dosages of statins in The Netherlands in 2009 was derived from the GIP-databank, a drug information system of the Dutch Health Care Insurance Board (http://www.gipdatabank.nl/), containing reimbursement data on almost the whole Dutch population. The average hypocholesterolemic effect of these different statins was estimated to be 24.6% (Illingworth and Tobert, 1994; Maron et al., 2000; Penning-van Beest et al., 2007) (Appendix A).
It was assumed that statins and phytosterols/-stanols had additive cholesterol-lowering effects, i.e. 29.3%, when used in combination (Eussen et al., 2010a; Neil et al., 2001; Simons, 2002) .
Discontinuation of phytosterols/-stanols and statins
In daily life, many subjects discontinue the use of phytosterols/ -stanols and/or statins (Luoto et al., 2004; Mantel-Teeuwisse et al., 2004) . Suffering from side effects such as myalgia, for example, is considered a reason for stopping statin therapy (Bates et al., 2009) . To adapt our scenarios to this daily life experience, we have included discontinuation rates for new users of phytosterol/-stanol and new statin users. For phytosterols/-stanols these were estimated from the percentage of subjects who stopped the use of phytosterols/-stanols between subsequent rounds in the Doetinchem Cohort Study. We assumed that subjects who discontinued phytosterols/-stanols, stopped in the first and second year with discontinuation rates of 33% after one year and 44% after two years. Subjects who adhere to the use of phytosterols/-stanols for at least two years, were assumed to continue use during the rest of their lives. In subjects who discontinued the use of phytosterols/-stanols, the total cholesterol level was assumed to return to the same level as before the start of the scenario.
Discontinuation rates for statins were 38.5% after one year and 53.5% after two years (Mantel-Teeuwisse et al. figure) . After a change in cholesterol level, subjects may either transit to another cholesterol class ( ) or remain in the same cholesterol class ( ). After initiating statin therapy, subjects transit from one of the right four classes ('Statin non-user') to one of the left four classes ('Statin user'). Subjects in all classes are at risk of cardiovascular disease, with different classes having different risks of developing cardiovascular disease (lower part of figure) . The model includes different relative risk estimates for chronic heart failure (CHF), stroke and acute myocardial infarction (AMI), and accounts for interactions between these diseases. Subjects are always of risk of death from cardiovascular disease-related and other-cause mortality. This risk depends on the class the subject belongs to. phytosterols/-stanols, we assumed total cholesterol levels to increase to the same level as before the start of the scenario in subjects who discontinued statin therapy. New combined users of statins and phytosterols/-stanols were assumed to stop both with a probability as if they were statin only users.
Health effects
Health effects were computed in terms of quality-adjusted lifeyears, a measure of the life expectancy of a person (in years) adjusted for the quality of life (Gold et al., 2002) , by using data from the Global and Dutch Burden of Disease studies (Lopez and Murray, 1998; Melse et al., 2000; Stouthard et al., 2000; van Baal et al., 2005; van Baal et al., 2006) . Total quality-adjusted life-years lived by the model population in each year of the simulation were found by tracking population sizes and disease prevalence. Net present values of quality-adjusted lifeyears were calculated by adding annual quality-adjusted life-years over the model's time horizon of 50 years, discounting future qualityadjusted life-years at 1.5% according to Dutch guidelines for pharmacoeconomic research (College voor Zorgverzekeringen, 2006) . Similarly, net present values of life-years saved were obtained.
Intervention costs and health care costs
We have calculated all intervention costs as well as both directly and indirectly related health care costs. Costs are expressed in Euros and are based on Dutch unit prices of 2010. Future costs were discounted at 4% annually according to the Dutch guidelines (College voor Zorgverzekeringen, 2006) .
Intervention costs included all costs related to the intervention, i.e. costs related to phytosterols/-stanols and, additionally for the theoretical maximum situation, all costs related to statin use. With respect to intervention costs for phytosterols/-stanols, we assumed that phytosterols/-stanols were incorporated into a bread spread. The additional costs of using the phytosterol/-stanol-enriched margarine instead of regular bread spread without phytosterols/-stanols was estimated at €6.20/kg (€9.68/kg for enriched margarine minus €3.48/ kg for regular margarine) which amounts to €31.68/yr for current phytosterol/-stanol intake levels (1.05 g phytosterols/-stanols per day equals 5.1 kg margarine per year). In addition, we assumed that all phytosterol/-stanol users had one doctor visit (€24,80) (Nederlandse Zorgautoriteit, 2009 ) and one lipid test (€24,98) (Nederlandse Zorgautoriteit, 2010) every 5 years costing in total €10,-/yr. Annual statin drug costs were estimated at €150/yr, based on the distribution of the different types and dosages of statin use in The Netherlands and the corresponding costs (http://www.gipdatabank.nl/). Statin users were assumed to have one doctor visit, one lipid test (Dutch Institute for Healthcare Improvement and Dutch College of General Practitioners, 2006) and three repeat prescriptions every year (€12.40 each) (Nederlandse Zorgautoriteit, 2009) , summing up to a total of €237,-/yr.
Health care costs included future savings related to diseases averted by using phytosterols/-stanols and/or statins and those resulting from surviving longer (indirect health care costs) (van Baal et al., 2007) . Lifetime health care costs were calculated in the Chronic Disease Model based on disease prevalence combined with age and gender specific data from the Dutch Cost of Illness Study (http://www.kostenvanziekten.nl/) (Poos et al., 2005; van Baal et al., 2005; van Baal et al., 2008) .
Calculation of cost-effectiveness
Cost-effectiveness ratios were calculated by dividing incremental costs (Euros) by health benefits (quality-adjusted life-years) gained due to the additional use of phytosterols/-stanols. First, intervention costs per quality-adjusted life-year gained were computed and second, total costs per quality-adjusted life-year gained, i.e. intervention costs plus all differences in health care costs. These cost-effectiveness ratios represent the value-for-money provided by adding treatment with phytosterols/-stanols to current statin use (real-life situation) as well as to maximal statin use resulting from screening (maximum situation).
Uncertainty and sensitivity analysis
Probabilistic uncertainty analysis was used to evaluate the combined effect of uncertainty regarding the effectiveness of phytosterols/-stanols and the use of the Doetinchem Cohort data to estimate the cholesterol levels in the Dutch population. For this uncertainty analysis, Monte Carlo simulation was used, with 100 independent simulations drawing for each simulation new parameter-values for the dose-response curve from their 95% confidence interval (CI). Each simulation used a new distribution over the eight cholesterol classes, assuming Dirichlet distributions for the conversion of the cholesterol distribution of the Doetichem Cohort to the Dutch population.
A series of univariate sensitivity analyses were performed to evaluate the impact of other important model assumptions and parameters on the results. The daily phytosterol/-stanol intake amount was set at the recommended level of 2 g/day. We assumed this was obtained by an increased concentration in bread spread at Table 2 The number of phytosterol/-stanol (PS) users and the effect of additional phytosterol/-stanol use on health effects, costs, and the cost-effectiveness ratios in the real-life (RL) and theoretical maximum (TM) situation, cumulative over the 50-year period of the simulation (as compared to the reference scenario for each situation, RL reference and TM reference). Costs were discounted at 4%, and life-years and quality-adjusted life-years at 1.5%. Data for the Dutch population aged 35-75 years (8.4 million people).
Real-life (RL)
Theoretical maximum (TM) equal costs. Discontinuation rates for phytosterols/-stanols and statins were set to zero and indirectly related health care costs were disregarded. Furthermore, discount rates on costs and effects of 0%, 3% and 5% were used, and a discount rate of 4% for costs combined with 0% for effects. Finally, time horizons of 10, 20 and 30 years were evaluated.
Results
Number of phytosterol/-stanol and statin users
At the start of the simulation (year 2007), about 615,000 members (7%) of the Dutch population aged between 35 and 75 years used functional foods enriched with phytosterols/-stanols in the reference scenarios (RL reference and TM reference) ( Table 2 ). Statins were used by approximately 1.2 million (14%) and 1.5 million (18%) persons in the real-life and theoretical maximum situation, respectively.
Due to the implementation of the scenarios the number of phytosterol/-stanol users increased. The number of extra phytosterol/ -stanol users in a real-life situation ranged between 1.0 million (RL plus PS (min)) and 2.6 million (RL plus PS (max)). In the theoretical maximum situation, a total of 3.3 million subjects started phytosterol/-stanol use (TM plus PS).
Health effects
For both the real-life and theoretical maximum situation, the discounted total health effects at the end of the simulation (after 50 years), expressed as life-years and quality-adjusted life-years gained, in the scenarios with additional phytosterol/-stanol use as compared to the reference scenarios (RL reference and TM reference) are shown in Table 2 . In the real-life situation, a total of 3600 life-years or 2700 quality-adjusted life-years (on average 0.0034 life-year or 0.0026 quality-adjusted life-year per extra phytosterol/-stanol user) were gained if all current statin users would start the use of phytosterols/-stanols (RL plus PS (min)). A total of 15,500 life-years or 12,400 quality-adjusted life-years (on average 0.0060 life-year or 0.0048 quality-adjusted life-year per extra phytosterol/-stanol user) were gained when additionally also all subjects with a modestly elevated risk (≥5, b10%) would start using phytosterols/-stanols (RL plus PS (max)). Additional phytosterol/-stanol use in the theoretical maximum situation resulted in a total of 16,300 qualityadjusted life-years (19,500 life-years) gained, or 0.0049 qualityadjusted life-year (0.0059 life-year) per extra phytosterol/-stanol user (TM plus PS). Fig. 2 shows the discounted extra quality-adjusted life-years gained per year by additional phytosterol/-stanol use compared to the reference scenario for each situation (RL reference or TM reference). In both situations, the quality-adjusted life-years gained by extra phytosterol/-stanol use reached a maximum after some 20 years when most people in the cohort are old but still alive, and some cardiovascular events can be delayed or prevented by the use of phytosterols/-stanols. Further in time, more and more people die and fewer events can be prevented.
Intervention costs and health care costs
The effect of additional phytosterol/-stanol use on cumulative discounted intervention and health care costs over the 50-year period in both situations are presented in Table 2 . Discounted intervention costs were about a factor 10 higher than health care costs, and ranged between €0.47 billion for added phytosterols/-stanols in the minimum real-life situation (RL plus PS (min)) to €1.26 billion for added phytosterols/-stanols in the theoretical maximum situation (TM plus PS). Intervention costs were the highest at the beginning of the simulation, declined steadily during the first two years due to discontinuation of phytosterol/-stanol and statin use, and gradually reached zero near the end of the simulation when most of the cohort has died (Fig. 3a ). Fig. 3b shows the difference in discounted health care costs per year in the scenarios with additional phytosterol/-stanol use compared to the reference scenarios (RL reference or TM reference). Apart from minor savings in health care costs during the first three years, health care costs were higher with additional phytosterol/-stanol use than without the additional use. This can be explained by the fact that subjects with a healthier cholesterol level live longer. During their longer lifetime they develop more diseases, with associated costs (van Baal et al., 2007) . The costs of these indirectly related health effects turn out to be higher than the prevented costs of cardiovascular events. Consequently, the more people that start using phytosterols/-stanols, the higher the health care costs.
Cost-effectiveness
Mean incremental total costs per quality-adjusted life-year for additional phytosterol/-stanol use varied between €96,000 and €203,000 in the real-life situation, and were about €92,000 in the theoretical maximum situation (Table 2) . When only the costs of the intervention itself were considered, mean costs were approximately €10,000 lower per quality-adjusted life-year, resulting in mean costs per quality-adjusted life-year between €84,000 and €192,000. Fig. 4 shows the cost-effectiveness of additional phytosterol/-stanol use for the different scenarios. The cost-effectiveness ratios were compared to threshold values of €20,000, €50,000 and €80,000 per additional quality-adjusted life-year (Boersma et al., 2010; van Gils et al., 2010) . In the maximum real-life situation (RL plus PS (max)) and the maximum situation (TM plus PS), the addition of phytosterols/-stanols had a probability between 30% and 44% of being cost-effective at a threshold value of €80,000. When a threshold for cost-effectiveness of €20,000 or €50,000 was considered, the addition of phytosterols/-stanols was not cost-effective in any of the 100 uncertainty simulation runs, neither in the real-life situation, nor in the theoretical maximum situation.
Uncertainty and sensitivity analyses
Results of the uncertainty and sensitivity analyses are shown in Table 3 . As expected, an increase in effectiveness of phytosterols/-stanols (total cholesterol reduction increased from 4.7% to 7.2%, the upper bound of the 95% CI) and an increased intake of phytosterols/-stanols (from 1.05 g/day to the recommended levels of 2 g/day) resulted in more favourable cost-effectiveness ratios. Assuming no discontinuation of phytosterols/-stanols or statins did only marginally affect the costeffectiveness ratio. Apparently, lifetime health benefits of the phytosterols/-stanols seem to be counterbalanced by the lifetime payment for phytosterols/-stanols. Disregarding indirect health care costs did not change the results, due to the fact that health care costs (both direct and indirect) were only 10% of the total costs. Considering a greater difference in discount rates for costs and effects, i.e. a higher discount rate for costs and a lower rate for effects, resulted in a more favourable costeffectiveness ratio, explained by the fact that the costs of the intervention are largely made in the first years, whereas a longer time-span is required to achieve effects of the intervention. Shorter time horizons led to a less cost-effective intervention, because much intervention costs are made at the start, whereas most of the health gains appear later.
Discussion
The present study suggests that the use of functional foods enriched with phytosterols/-stanols as monotherapy and as add-on to statin therapy is a non-cost-effective strategy to reduce cardiovascular disease. In a situation in which persons eligible for use were identified through passive clinical case-finding, the cost-effectiveness of phytosterols/-stanols ranged from about €96,000 to €203,000 per quality-adjusted life-year. A slightly lower (more favourable) costeffectiveness ratio of €92,000 was obtained when subjects qualifying for phytosterols/-stanols were found through a (hypothetical) universal screening program for cardiovascular disease (costs of the universal screening program were not included in the analyses). In Table 3 Results for cost-effectiveness ratio of the uncertainty and sensitivity analyses. The influence of changes in effectiveness and intake level of phytosterols/-stanols, discontinuation, discount rates and time horizon on the cost-effectiveness ratio (total extra costs per quality-adjusted life-year gained) of additional phytosterol/-stanol use in the real-life (RL) and theoretical maximum (TM) situation (as compared to the reference scenarios). Data are cumulative over the 50-year period of the simulation.
Real-life (RL)
Theoretical maximum (TM) both situations, cost-effectiveness ratios are well above established threshold values for cost-per-quality-adjusted life-year, which generally range between €20,000 and €50,000 (Boersma et al., 2010; van Gils et al., 2010) . These threshold values for cost-effectiveness ratios were also not reached in sensitivity analyses in which treatment effect or intake level of phytosterols/-stanols was increased, or future health care costs were not taken into account. This is the first study evaluating whether functional foods enriched with phytosterols/-stanols are a cost-effective strategy in addition to the beneficial effects of statins in the prevention of cardiovascular disease. Two studies have been performed to assess the cost-effectiveness of phytosterols/-stanols alone (Gerber et al., 2006; Martikainen et al., 2007) . Gerber et al. (Gerber et al., 2006) found that €52 per person could be saved when phytosterol/-stanol-enriched margarine was consumed by the entire German population between 30 and 79 years of age. In contrast to our study Gerber et al. disregarded intervention costs, i.e. costs of the functional foods enriched with phytosterols/-stanols and costs for doctor visits and lipid tests. Martikainen et al. (Martikainen et al., 2007) found cost-effectiveness ratios between €7436 and €112,151, conditional on age and gender, and concluded that phytosterol/-stanolenriched functional foods were a cost-effective option for high-risk persons (adult men and women aged 60 years or older). One of the reasons for the difference between the results of these two studies and the present one is that, although phytosterols/-stanols are recommended for subjects with elevated cholesterol levels (Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, 2002; Clifton, 2009) or elevated SCORE-risks (Dutch Institute for Healthcare Improvement and Dutch College of General Practitioners, 2006; Law, 2000) , all persons in a certain age group were treated with phytosterols/-stanols in the previous studies, regardless of a person's cholesterol level or SCORE-risk (Gerber et al., 2006; Martikainen et al., 2007) . Moreover, both previous studies assumed perfect adherence to phytosterols/-stanols, i.e. the continuous use of the recommended daily amount of 2 g phytosterols or -stanols. Actual adherence is, however, known to be less than optimal (Luoto et al., 2004; Wolfs et al., 2006) . People do stop the use of phytosterols/-stanols and consume less than the recommended intake amount. Finally, neither previous study considered costs caused by diseases other than cardiovascular disease, acquired later in the life-years saved. Yet, it is more and more recommended that these indirectly related health care costs should be included in economic evaluations (van Baal et al., 2007; Feenstra et al., 2008; Nyman, 2004; Meltzer, 2008) . Nevertheless, with respect to the latter two aspects, sensitivity analyses which disregarded discontinuation of phytosterols/-stanols or indirect health care costs did not substantially alter the results.
We assumed that phytosterols/-stanols were incorporated into a bread spread. Although enriched bread spreads are the most commonly used source for phytosterols/-stanols today, the market is expanding to include other dairy products, like yoghurt (drinks) and milk. Nevertheless, costs (in Euros 2010) for recommended daily intake levels of enriched yoghurt drinks and milk are €0.60 and €1.05, respectively, which is notably higher than costs for recommended intake levels of the bread spread (€0.25). Consequently, this would result in even more unfavourable cost-effectiveness ratios.
In the present study, the cost-effectiveness of phytosterols/-stanols was evaluated both in a real-life situation and in a theoretical maximum situation. In the maximum situation, persons eligible for statin treatment or lifestyle modifications (phytosterols/-stanols) were selected following the Dutch guidelines for cardiovascular risk management. However, it is known that not all general practitioners follow these guidelines and use the SCORE risk calculation charts that accompany the guidelines (Hobbs and Erhardt, 2002; Scheltens et al., 2009) . Besides general practitionerrelated factors, also patient-related factors may have contributed to the fact that in the present study, one fifth (n=321,000) of the subjects eligible for statin use were not using them. Patients may refrain from starting statin therapy, or may discontinue the medication because of side effects or lack of effect (Finn et al., 2009 ). In addition, a few deviations between the guidelines and the implementation of the guidelines in our scenarios should be mentioned. Firstly, the guidelines offer separate recommendations for subjects with and subjects without type 2 diabetes mellitus or established cardiovascular disease. In the current analysis, all patients suffering from type 2 diabetes or cardiovascular disease were considered to have the same probability of receiving phytosterols/-stanols and statins as the general population. Thus, we underestimated the chance of being treated for these patients. Furthermore, the guidelines consider subjects with a 10-year SCORErisk of fatal cardiovascular disease ≥10% eligible for statin treatment, unless their LDL-cholesterol level is b2.5 mmol/l. We were not able to include this limitation as in the Doetinchem Cohort Study, which was assumed to represent the Dutch population, only subjects' total and HDL-cholesterol level was assessed. However, under the assumption that 80% of the circulating cholesterol in the human body is bound to LDL (Crowley, 2009) , less than 1% of the Dutch population with a SCORE-risk ≥10% has a LDL-cholesterol level below 2.5 mmol/l. This would not have affected the estimated cost-effectiveness of phytosterols/-stanols.
We have used the Chronic Disease Model to project future effects on health and health care costs. Some limitations of the use of this model need to be addressed. Most importantly, continuous risk factors, such as total cholesterol level, in the Chronic Disease Model are categorized into four classes (Fig. 1) . As a consequence, subjects already in the lowest cholesterol risk factor class before the start of the simulation cannot gain benefits from the phytosterols/-stanols. This may result in an underestimation of the effects of phytosterols/-stanols. Nonetheless, there is currently no evidence that lowering total cholesterol levels below the established target values of 5 mmol/l is associated with lower mortality (Jacobson, 2000; Warren, 2008) . Moreover, estimates of relative risks of cardiovascular disease in the Chronic Disease Model are based on studies from different countries. Although this results in the best approximation of the available data, it is unknown whether this approach gives the best values for the Dutch relative risk estimate. Finally, in using the Chronic Disease Model, some assumptions had to be made. Firstly, it was assumed that the association between cholesterol-lowering effects of phytosterols/-stanols and reduction in cardiovascular disease was similar to the associations seen for other cholesterol-lowering strategies and cardiovascular disease risk reduction. Secondly, we assumed that subjects entering the model were similar to those enrolled in the Doetinchem Cohort Study with respect to SCORE-risk and phytosterol/-stanol and statin use. However, the Doetinchem Cohort is not entirely representative for the Dutch population. Smokers and the lower educated appear to be underrepresented in the cohort (Verschuren et al., 2008) . Since smoking is associated with increased total cholesterol levels (Craig et al., 1989) and phytosterol/-stanolenriched margarines are less often used by the lower educated , SCORE-risks and the percentage of phytosterol/-stanoland statin-users in the Dutch population are likely to be slightly different than those estimated from the Doetinchem Cohort Study.
In conclusion, this simulation study shows that the intake of functional foods enriched with phytosterols/-stanols for those with elevated cardiovascular disease risk, as encouraged in the guidelines for cardiovascular risk management, is above Dutch and international thresholds for cost-effectiveness, and is thus a non-cost-effective strategy to reduce cardiovascular disease. This study demonstrates the importance of incorporating cost-effectiveness assessments in health care resource allocation decision-making. Comparing the costeffectiveness of phytosterol/-stanol-enriched functional foods to other (functional) foods and drugs is suggested to be a critical step in assessing their broader applicability.
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